Type Ⅰ Gaucher disease is an inherited disease caused by an abnormal accumulation of glucosylceramide in bone marrow cells and visceral organs due to the deficiency of glucocerebrosidase.Currently,the common treatments of type Ⅰ Gaucher disease are enzyme replacement therapy or bone marrow transplant,which are both time consuming and expensive.Although N-butyldeoxyjirinomycin (miglustat) is approved by the US Food and Drug Administration for the treatment of Gaucher disease,still,the expensive cost has made it difficult for the patients to access.